The Team



Yuti Chernajovsky


Trained as a molecular biologist, his research activities have included the cloning of several cytokines and their receptors. He contributed to the development of interferon β as a therapeutic agent and the use of suicidal genes for cancer gene therapy. His research interests have mainly been to apply scientific findings to develop and improve disease treatments in autoimmunity and cancer, including the development of gene transfer strategies via molecular design and cellular engineering.

Michele Hill-Perkins


Michele has experience as a research scientist in both academia and the biotechnology industry. She has held senior business development roles at Cancer Research Technology and the Wellcome Trust where she was involved in leading licensing transactions and the provision of "development gap" funding to spin-out companies in the biotechnology and pharma sector. Prior to joining QMI, Michele worked as Project Director at Partnerships UK, advising public sector organisations on commercial strategy, and also in its venture capital arm, PUK Ventures, advising on life science and medtech investments.

Mike Capaldi


Started his career as a medical research scientist before moving into more commercial roles and general management.  He has worked in both multinational pharmaceutical companies (Ciba Geigy, SmithKline Beecham and Nycomed Amersham) as well as biotech companies, both in Europe and the USA.  As CEO of a number of these companies, he has experience of IPOs as well as driving exits via trade sales.  More recently, he has been working with Edinburgh University to commercialise medical technologies.  He also sits as non-executive director on a number of company Boards.